PRESS RELEASE published on 12/09/2025 at 07:30, 11 months 1 day ago OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation OSE Immunotherapeutics unveils 2026–2028 strategic plan focusing on Tedopi's phase 3, rare indications for Lusvertikimab, subcutaneous formulation in UC, and maintaining scientific leadership Strategic Plan Scientific Leadership OSE Immunotherapeutics Tedopi Phase 3 Lusvertikimab Indications
BRIEF published on 10/15/2025 at 19:05, 1 year ago OSE Immunotherapeutics Reports 2025 First Half Financial Results Revenue Decline OSE Immunotherapeutics Cash Runway R&D Expenses 2025 Financial Results
BRIEF published on 10/15/2025 at 19:05, 1 year ago OSE Immunotherapeutics publie ses résultats financiers du premier semestre 2025 Baisse Des Revenus OSE Immunotherapeutics Dépenses De R&D Piste De Trésorerie Résultats Financiers 2025
PRESS RELEASE published on 10/15/2025 at 19:00, 1 year ago OSE Immunotherapeutics Reports First Half 2025 Financial Results OSE Immunotherapeutics reports first half 2025 financial results with operating loss of 15.8 million euros and net loss of 15.1 million euros. Research and development expenses increased 6.7% Financial Results Net Loss Operating Loss OSE Immunotherapeutics Research And Development Expenses
PRESS RELEASE published on 10/15/2025 at 19:00, 1 year ago OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025 OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025, montrant une perte nette de 15,1 millions d'euros. Les activités sont estimées financées jusqu'au 4ème trimestre 2026 Résultats Financiers Biotechnologie Perte Nette OSE Immunotherapeutics Horizon De Trésorerie
BRIEF published on 10/09/2025 at 16:02, 1 year 1 month ago OSE Immunotherapeutics : Fin d'une action de concert entre actionnaires Actionnaires Franchissement De Seuil Capital Et Droits De Vote OSE Immunotherapeutics Pacte Résilié
BRIEF published on 10/09/2025 at 16:02, 1 year 1 month ago OSE Immunotherapeutics: End of a concerted action between shareholders Shareholders Threshold Crossing OSE Immunotherapeutics Capital And Voting Rights Terminated Agreement
PRESS RELEASE published on 10/09/2025 at 15:57, 1 year 1 month ago Franchissement de seuils Fin de convention et action de concert chez OSE Immunotherapeutics suite à franchissement de seuils de M. Emile Loria, Mme Dominique Costantini, M. Alexis Peyroles, MS Medical Synergy SA et Aperana Consulting SARL OSE Immunotherapeutics Franchissement Seuils Fin Convention Action Concert Emile Loria
BRIEF published on 09/30/2025 at 19:35, 1 year 1 month ago OSE Immunotherapeutics : Réorganisation du Conseil d'administration Biotechnologie Conseil D'administration Immunothérapie OSE Immunotherapeutics Markus Cappel
Published on 11/11/2026 at 00:40, 40 minutes ago Upgraded Tunkillia MRE Validates Optimised Scoping Study
Published on 11/10/2026 at 23:30, 1 hour 50 minutes ago CCL Industries Announces 2026 Third Quarter Results
Published on 11/10/2026 at 23:00, 2 hours 20 minutes ago Vanta Announces Appointment of Chief Financial Officer and Corporate Secretary
Published on 11/10/2026 at 23:00, 2 hours 20 minutes ago Battery X Metals Announces Appointment of Chief Financial Officer and Corporate Secretary
Published on 11/10/2026 at 23:00, 2 hours 20 minutes ago Condor Agrees to Short Extension of Lucero Closing Payment with ELEMENT79 and Provides Huiñac Punta Drill Program Update
Published on 11/11/2026 at 00:15, 1 hour 5 minutes ago Lean Focus Launches Asia Pacific: Local Expertise. Global Impact.
Published on 11/10/2026 at 23:15, 2 hours 5 minutes ago GSMA MWC26 Doha welcomed over 10,000 attendees, as world-first ITU co-location puts MENA at the centre of global connectivity policy and innovation
Published on 11/10/2026 at 19:21, 5 hours 58 minutes ago ALTHEORA, Mäder Composites France et IPC s'associent pour donner une seconde vie aux matériaux composites
Published on 11/10/2026 at 18:00, 7 hours 20 minutes ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 7 hours 35 minutes ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 7 hours 45 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 7 hours 48 minutes ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
